Cerdelga eliglustat tartrate regulatory update

FDA approved Cerdelga eliglustat from Sanofi’s Genzyme Corp. unit to treat Type I Gaucher’s disease. Genzyme plans to launch the oral ceramide analog that inhibits glucosylceramide synthase (GCS) in the U.S. within a month of its approval on Aug. 19. The product is also under review in Europe for the indication. ...